| Name | Title | Contact Details |
|---|
Enalare Therapeutics Inc. is a privately owned clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions.
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
RxAdvance, a national full service PBM, leverages the disruptive Collaborative PBM Cloud™ to manage standard and specialty drug benefits with unmatched regulatory compliance and transparency. In addition, RxAdvance is willing to share global pharmacy risk, avoidable drug-impacted medical risk, and bundled episode specialty pharmacy risk, standing shoulder-to-shoulder with plan sponsors as a true accountable partner. This risk model has never been offered by any other PBM.
Archemix Corp. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kalypsys, Inc. is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.